Table 2.
Condition × CBCL Externalizing Clinical Threshold |
Assessment Point | Effect Size (d) | |||
---|---|---|---|---|---|
Baseline M (SD) |
5 Months M (SD) |
12 Months M (SD) |
t0 to t5 | to t12 | |
SAU-Below (SB) | 7.13 (3.88) | 6.23 (7.27) | 5.60 (6.36) | 0.20 | 0.34 |
BOOST Below (BB) | 8.94 (4.62) | 8.19 (7.26) | 7.80 (8.42) | 0.17 | 0.26 |
SAU Above (SA) | 27.09 (8.26) | 18.36 (11.44) | 22.34 (14.86) | 0.99 | 0.54 |
BOOST Above (BA) | 27.80 (9.07) | 19.71 (10.62) | 21.37 (14.02) | 0.92 | 0.73 |
d = (SB- BB) | −0.41 | −0.44 | −0.49 | 0.03 | 0.09 |
d = (SA – BA) | −0.08 | −0.15 | 0.11 | 0.07 | −0.19 |
Note: Cell entries are the means (M) or standard deviations (SD) for the externalizing measure. The effect size estimates are based upon Cohen’s d criteria and compare change from baseline (t0) to the fifth (t5) or the 12th (t12) month. The denominator was the baseline composite for clients below (SD = 4.46) or above (SD = 8.79) clinical thresholds. The bottom rows reports the effect size differences between the SAU and BOOST conditions at each assessment point for clients that are either above (A) or below (B) the clinical threshold. The baseline sample sizes were SB = 21; BB = 37; SA = 38; BA = 68.